Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Histamine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    198 result(s) found for: Histamine. Displaying page 7 of 10.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next»
    EudraCT Number: 2019-003036-23 Sponsor Protocol Number: 19SM5101 Start Date*: 2019-12-02
    Sponsor Name:Imperial College London
    Full Title: Mechanisms of adverse effects of long-acting beta-agonists in asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003638 Atopic asthma LLT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003565 Asthmatic LLT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10015575 Exacerbation of asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-003066-34 Sponsor Protocol Number: 101-PG-PSC-150 Start Date*: 2007-01-23
    Sponsor Name:LETI Pharma GmbH
    Full Title: A randomized, double blinded, placebo controlled multicenter study for the efficacy and safety of Depigoid® House dust mites (HDM) in patients suf-fering from moderate to severe atopic eczema.
    Medical condition: Moderate to severe atopic eczema with or without rhinitis and/or rhinoconjunctivitis caused by clinical relevant IgE-mediated sensitization against House dust mites (HDM) leading to aggravation of ...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003641 Atopic eczema LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003063-34 Sponsor Protocol Number: GSDL_DE_17 Start Date*: 2017-12-11
    Sponsor Name:Lofarma S.p.A.
    Full Title: A double-blind, placebo-controlled dose-escalation study of carbamylated monomeric tree pollen drops in patients with a history of allergic rhinoconjunctivitis.
    Medical condition: Treatment of tree pollen-induced allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-005079-21 Sponsor Protocol Number: LOTAB_2b_HDM Start Date*: 2018-08-23
    Sponsor Name:Lofarma S.p.A.
    Full Title: A Prospective, Multicenter, Double-Blind, Placebo-Controlled, Dose-Finding Phase-II Study for the Efficacy and Safety of LAIS® House Dust Mites Sublingual Tablets in Patients with Mite-Induced Alle...
    Medical condition: Patients Suffering from Mite-Induced Allergic Rhino-Conjunctivitis Without or With Controlled Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005084-32 Sponsor Protocol Number: D6230C00001 Start Date*: 2015-06-05
    Sponsor Name:AstraZeneca AB
    Full Title: A randomized, double-blind, placebo-controlled, parallel group, multi-centre Phase IIa study in asthma patients comparing the efficacy and safety of once daily inhaled Interferon beta-1a to placebo...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-002047-18 Sponsor Protocol Number: SM/0044 Start Date*: 2015-01-14
    Sponsor Name:HAL Allergy B.V.
    Full Title: A randomized, double-blind, placebo-controlled study to determine tolerability and safety of different dosages of SUBLIVAC FIX Mite mixture in patients with allergic rhinitis / rhinoconjunctivitis ...
    Medical condition: Patients, 18-60 years of age, suffering from house dust mites-induced persistent allergic rhinitis/rhinoconjunctivitis with or without concomitant at least partly controlled asthma.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10020419 House dust mite allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002252-36 Sponsor Protocol Number: T502-SIT-045 Start Date*: 2021-10-27
    Sponsor Name:Inmunotek S.L.
    Full Title: A prospective, randomized, double-blind placebo-controlled multicentre study with 10 000 mTU/mL mannan-conjugated birch pollen allergoids administered subcutaneously to patients with birch pollen-i...
    Medical condition: Treatment of birch pollen-induced allergic rhinitis or rhinoconjunctivitis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001291-38 Sponsor Protocol Number: Salsa Start Date*: 2018-08-08
    Sponsor Name:Radboud University Medical Center
    Full Title: In vivo efficacy of Salbutamol Sandoz versus salbutamol Ventolin GSK in children with asthma
    Medical condition: Asthma in children
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002522-23 Sponsor Protocol Number: T502-SIT-020 Start Date*: 2019-08-21
    Sponsor Name:Inmunotek S.L.
    Full Title: A prospective, randomized, double-blind placebo-controlled dose-finding study of different regimens of mannan-conjugated allergoids of birch pollen allergens administered subcutaneously to patients...
    Medical condition: Treatment of birch pollen-induced allergic rhinitis or rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006681-21 Sponsor Protocol Number: FVGEXACT@home2021 Start Date*: 2022-11-17
    Sponsor Name:Franciscus Gasthuis & Vlietland
    Full Title: Expertise Asthma COPD Program with Digital Support
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004855 10003555 Asthma bronchial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000353-20 Sponsor Protocol Number: VR475/3/001 Start Date*: 2015-10-01
    Sponsor Name:Vectura Limited
    Full Title: A randomised, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two doses of nebulised budesonide delivered by the VR475 Inhalation System, with an open-...
    Medical condition: Uncontrolled Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) BG (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-000571-85 Sponsor Protocol Number: AN-EPI3333 Start Date*: 2017-06-15
    Sponsor Name:ANTHERA Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Open-Label, Assessor-Blind, Non-Inferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects with Cystic Fibrosis-Related Exocrine Pancr...
    Medical condition: Pancreatic Exocrine Insufficiency due to Cystic Fibrosis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) GB (Prematurely Ended) LT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-001360-21 Sponsor Protocol Number: CD-RI-CAT-354-1049 Start Date*: 2011-09-07
    Sponsor Name:AstraZeneca AB R&D Mölndal
    Full Title: A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults with Uncontrolled, Severe Asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) CZ (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-002911-33 Sponsor Protocol Number: ABT-gpASIT011 Start Date*: 2018-12-18
    Sponsor Name:ASIT biotech S.A.
    Full Title: A multicentre, international, randomised, double-blind, placebo controlled study to demonstrate the clinical efficacy and safety of subcutaneous immunotherapy with gpASIT+™ in patients with grass p...
    Medical condition: Treatment of seasonal grass pollen-induced rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10019170 Hay fever LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) BE (Prematurely Ended) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-002088-18 Sponsor Protocol Number: H3A106104 Start Date*: 2006-10-12
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: An open label, dose escalation study with a double blind randomised placebo controlled withdrawal to examine the effects of the histamine H3 antagonist GSK189254 in patients with narcolepsy.
    Medical condition: Narcolepsy
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028713 Narcolepsy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) NL (Prematurely Ended) AT (Completed) FI (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-001251-40 Sponsor Protocol Number: MEA115588 Start Date*: 2012-10-16
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncon...
    Medical condition: Subjects with severe, refractory, uncontrolled asthma with elevated blood eosinphils
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DE (Completed) ES (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-002242-36 Sponsor Protocol Number: GB001-2001 Start Date*: 2018-12-06
    Sponsor Name:GB001, Inc.
    Full Title: A Phase 2b, randomized, double-blind, placebo-controlled, dose-ranging, multi-center study to evaluate the efficacy and safety of GB001 as maintenance therapy in adult subjects with moderate to sev...
    Medical condition: Eosinophilic Asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) BE (Completed) AT (Completed) ES (Completed) GB (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-008448-26 Sponsor Protocol Number: 603-PG-PSC-173 Start Date*: 2009-10-20
    Sponsor Name:LETI Pharma GmbH
    Full Title: Randomized, double-blind, parallel group, multicenter study to evaluate the efficacy and safety of four doses of depigmented glutaraldehyde polymerized birch pollen allergenic extract (Depigoid® Bi...
    Medical condition: Allergic rhinitis and/or rhinoconjunctivitis, with or without intermittent asthma, caused by birch pollen.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001723 Allergic rhinitis LLT
    9.1 10039097 Rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003208-37 Sponsor Protocol Number: AL0704rP Start Date*: 2008-01-18
    Sponsor Name:Allergopharma Joachim Ganzer KG
    Full Title: A multicentre multinational randomised, placebo-controlled, double-blind pivotal trial for the evaluation of safety and efficacy of specific immunotherapy with a cocktail of recombinant major aller...
    Medical condition: ICD classification code: J45.0 and J 30.1
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10001728 Allergic rhinoconjunctivitis LLT
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004117-33 Sponsor Protocol Number: H3B109689 Start Date*: 2007-12-17
    Sponsor Name:GlaxoSmithKline R&D Ltd
    Full Title: A single blind, placebo-controlled, randomised study in mild to moderate Alzheimer's disease patients to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK239512, a selec...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 10:23:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA